APPLICATION
Application Note
The peptide is used for blocking the activity of DR6 (GTX28417). Incubatingthe peptide with equal volume of antibody for 30 min at 37ºC usually completely blocks theantibody activity in Western blotting.
PROPERTIES
Form
Liquid
Buffer
PBS pH7.2, 10mM NaH₂PO₄, 10mM Na₂HPO₄, 130mM NaCl, 0.1% BSA
Preservative
0.02% Sodium azide
Storage
Store the peptide at -20ºC, stable for one year.
Concentration
0.20 mg/ml (Please refer to the vial label for the specific concentration.)
Conjugation
Unconjugated
Note
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET
Synonyms
Tnf Receptor Superfamily Member 21 , Bm-018 , Cd358 , Dr6 , Tnfrsf21
Background
Apoptosis is induced by certain cytokines including TNF and Fas ligand of the TNF family through their death domain containing receptors, TNFR1 and Fas. Several novel death receptors including DR3, DR4, and DR5 were recently identified. A new death domain containing receptor in the TNFR family was cloned recently and termed DR6 for death receptor 6. Like TNFR1, DR6 interacts with death domain containing adapter molecule TRADD. Overexpression of DR6 induces apoptosis and activates NF-kB and JNK. DR6 is widely expressed inhuman tissues and cell lines. The ligand for DR6 hasnot been identified.
Research Area
REFERENCE
There are currently no references for DR6 peptide (GTX28450). Be the first to share your publications with this product.
REVIEW
There are currently no reviews for DR6 peptide (GTX28450). Be the first to share your experience with this product.